A Chinese court has loosened the scope of “product similarity” in trademark law to include virtual models of actual trademarked products. | China’s conviction of a crypto laundering defendant reflects stricter enforcement in cryptocurrency-related crimes. | New draft regulations allow for loans for minority M&A stakes.
Qiong Wu, Yuxiang Liu, Qingqing Chen and Xiaoyi Zhuang of Haiwen & Partners provide essential insights into an essential new judicial interpretation concerning labor dispute cases, including a comparison with the current rules and judicial practice and implications for compliance and risk management practices
Court interpretation of rules governing mandatory social insurance payments causes backlash; Proposed changes to implementation of China’s VAT regime aim to clarify gray areas; and Arkansas joins push to divest pension funds from China.
Eric (Ye) Zou of Merits & Tree Law Offices gives an overview of the core elements and key significance of a new pilot scheme which maps out a new way for foreign investors to access China’s flourishing financial markets
In the first part of a series of articles, Jianwei (Jerry) Fang, Ke Dong, and Haoyi Sun of Zhong Lun Law Firm outline the general jurisdiction rules governing foreign-related civil litigation in China under the 2024 Civil Procedure Law, and explain the statutory framework, key jurisdictional bases, and procedural considerations that foreign companies and in-house counsel need to understand when facing potential lawsuits in Chinese courts
FRAND ruling undercuts London’s global ambitions as Samsung’s U.K. win against ZTE risks backfiring in Germany; U.S. consultancy giant asks staff to pause generative AI-related consultancy work in China; and U.S. toymakers diversify away from China amid tariff challenges
China rolls out tax breaks for foreign investors reinvesting profits locally; China remains key private equity market but firms are starting to diversify investments; U.S. Congressional bill that targets Chinese AI tools like Deepseek has bipartisan support
CEO and General Counsel of MyoMed Bio, explains how legal strategy—spanning IP, regulatory compliance, and cross-border structuring—is essential for enabling clinical development, managing geopolitical and data protection risks, and aligning biotech operations across China, the U.S., and Australia.
